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DNA demethylating agents are approved for some blood malignancies and are under active inves-
tigation in solid tumors, but how these drugs work has remained unclear. In this issue of Cell, two
groups show that these agents activate a toxic cellular antiviral program through transcriptional
activation of endogenous retroviral sequences.DNA methylation on cytosine residues
at regulatory elements represents a
critical layer of control of gene ex-
pression for processes such as X in-
activation, imprinting, and differentiation.
Methylated cytosines recruit protein com-
plexes that promote functionally inert
heterochromatin.
Studies dating back decades showed
that cancer cells have a global decrease
in DNA methylation, but at specific
genes, DNA methylation is increased in
association with silencing of genes that
control cell growth, often including tumor
suppressors (Timp and Feinberg, 2013).
Aberrant DNA methylation patterns have
been hypothesized to allow cells to
sample novel states of DNA methylation
and gene expression, some of which
may stimulate the initiation or progres-
sion of malignancy. This model posits
that removal of the aberrant DNA methyl
mark by agents such as 5-azacitidine
(AZA) and decitabine (DEC) will inhibit
tumor cells by reactivation of silenced
tumor suppressor programs and poten-
tially synergize with conventional thera-
pies. However, the effects of demethylat-
ing agents are diverse, and identification
of genes whose reactivation predicts or
mediates response has been elusive.
Furthermore, low-dose AZA or DEC treat-
ment can induce long-lasting decreases
in self-renewal and tumorigencity of tu-
mor-initiating cells without cytotoxicity
or changes in cell cycle, as predicted by
acute reactivation of tumor suppressors
(Tsai et al., 2012). This correlates with
the slow onset of therapeutic responses
to demethylating agents in acute myeloid
leukemia and myelodysplasia and persis-938 Cell 162, August 27, 2015 ª2015 Elsevietence of response after therapy ends. In
this issue of Cell, new data from two
groups, Roulois et al. and Chiappinelli
et al., indicate that demethylating agents
can induce a cell-autonomous immune
activation response by stimulating ex-
pression of endogenous retroviruses.
This anti-viral response may underlie
some of the anti-tumor activity of these
drugs.
A link between demethylating agents
and the immune system was made over
a decade ago in experiments that
showed that AZA could demethylate
and activate genes encoding MHC class
I genes and tumor antigens (Karpf et al.,
1999, 2004). Interferon pathway genes
were also upregulated by AZA, and this
was correlated with increased expres-
sion of endogenous retroviral transcripts
rather than de-repression of interferon
pathway transcription factors. More
recently it was shown that among the
most common set of genes induced by
AZA in solid tumor cell lines were those
involved in antigen presentation and
interferon response (Li et al., 2014). This
finding was corroborated by the obser-
vation that patients who had previously
received AZA for lung cancer subse-
quently had a response to immune
checkpoint inhibitors (Wrangle et al.,
2013).
In Roulois et al. (2015), gene expres-
sion profiling of colorectal and ovarian
carcinoma cells treated with low-dose
AZA identified genes upregulated with
delayed kinetics whose expression was
not correlated with changes in DNA
methylation, many of which were targets
of the IRF7 protein, a known antiviralr Inc.mediator. Probing upstream, these in-
vestigators found that AZA induced nu-
clear localization of IRF7 by stimulation
of the MDA5 and RIG-I proteins that
recognize double stranded viral RNA
(Figure 1). The anti-proliferative response
to AZA depended on the RIG-I/MDA5
RNA response pathway, and moreover,
double-stranded RNA (dsRNA) itself
mimicked the effect of AZA in inhibiting
self-renewal of colorectal cells. Chiappi-
nelli et al. (2015) found that colon cancer
cells treated with AZA actually began to
secrete interferon, but this was not linked
to demethylation of interferon pathway
genes. Again, the evidence pointed to
activation of endogenous retroviral se-
quences, as transfection of a fresh cul-
ture of cells with dsRNA derived from
AZA-treated cells, but not control cells,
induced an antiviral response in recipient
cells.
These studies highlight another mode
of action of demethylating agents in can-
cer and suggest new rational approaches
to the use of such agents in immuno-
therapy. Indeed, Chiappinelli et al. pro-
vide evidence that inhibition of DNA
methylation could sensitize a murine
model of melanoma to anti-CTLA4 im-
mune checkpoint therapy. Interferon it-
self has a limited role in cancer therapy,
so why would AZA and as an indirect
activator of cell autonomous antiviral im-
munity offer a benefit? The multi-faceted
effects of demethylating agents might
promote their potency by simultaneously
inducing an antiviral, anti-proliferative
state, reactivating tumor antigen expres-
sion and altering cell signaling pathways
and apoptotic thresholds. Patients with
Figure 1. An Immune Facet of the Cellular
Response to DNA Demethylating Agents
DNA demethylating agents allow bidirectional
transcription from endogenous retroviral seq-
uences driven by the long terminal repeat (LTR)
sequences, which are usually heavily methylated
and inactivated. Proteins such as RIG-I and MDA5
sense the presence of dsRNA and interact with the
MAVS anti-viral response protein at the mito-
chondria. MAVS mediates activation of IRF7 and
induction of an antiviral state, including the secre-
tion of interferon, which in turn contributes to
reduced cell proliferation.low expression of MHC genes, low activ-
ity of antiviral pathways, and with a high
tumor mutation burden that can create
neoantigens might be the best candi-
dates for the use of AZA in combination
with antibodies directed against immune
checkpoint regulators. These ideas are
being tested in a clinical trial of anti-PD1
following a demethylating agent in lung
cancer (NCT01928576). It will be critical
to perform prospective immune moni-
toring in patients treated with demethy-
lating agents, particular in light of the
fact that Wrangle et al. (2013) showed
that, in addition to increasing expres-
sion of tumor antigens, AZA can increase
expression of the immunosuppressive
PDL1. Furthermore, AZA promoted
the development of immunosuppressive
Treg cells in vitro and in patients (Stu¨big
et al., 2014).
The findings from Roulois et al. and
Chiapellini et al. should propel new
studies to determine how AZA and DEC
work in myeloid malignancy, where their
mode of action remains obscure. For
example, one study of the combination
of AZA with a histone deacetylase inhibi-
tor showed that the most reliable marker
of response was evidence of increased
DNA damage (Fandy et al., 2009), and
the tumor suppressor reactivation model
has yet to be proven in leukemia or any
other malignancy. Whether the immuneCell 16systems and retrovirus activation play
any role in the activity of AZA and DEC
in myeloid malignancy seems worth
investigating. Lastly, given these new
data, monitoring treated patients for
the activation of retroviral transposable
elements that could cause further dam-
age to the cancer genome should be
considered.REFERENCES
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